Tag Archive for: sino biological

Endotoxin-Free Proteins Made in the USA
Biomedical Research and Therapeutics

ProPure™: Raising the Bar in Life Science Research

,

In biomedical research and biomanufacturing, the purity of reagents directly impacts the reliability of experimental outcomes and the safety of downstream therapeutic products. Endotoxins are notorious contaminants in protein preparations. Even trace amounts of endotoxin in recombinant proteins can trigger potent immune responses, distort results, and compromise patient safety, especially in sensitive applications such as immunology, cell and gene therapy, and vaccine production. Sino Biological has addressed this urgent need with the launch of ProPure™, an advanced line of endotoxin-free recombinant proteins.

Read more
Schematic diagram of CAR structure (Source: doi: 10.1186/s40364-017-0102-y)
CAR-T cell therapy

A Universal Solution Emerges: Anti-Linker Antibodies Simplify CAR-T Detection and Development

CAR-T cell therapy has demonstrated remarkable success in treating hematologic malignancies and is now expanding into solid tumors. On June 1, 2025, The Lancet published positive results from the world’s first randomized controlled trial of CLDN18.2 specific CAR-T in gastric cancer, led by Professor Lin Shen’s team at Peking University.

Read more
EB.com_Sino_Advertorial_ab_September_25Sino Biological
Drug Discovery

PROTACs and MGDs: The Revolutionary Modalities for Drug Discovery

Stick, Tag, Destroy: The Science of PROTACs and MGDs – For a long time, traditional drug research focused on inhibitors that block the active sites of disease-related proteins. However, around 80% of these proteins remain “undruggable” because they lack clear binding sites.

Read more
970 540Sino Biological
Sino Biological

ADC Applications Beyond Oncology

,

Antibody-Drug Conjugates (ADCs) have been transformative in oncology, offering targeted cancer treatments that enhance efficacy while sparing healthy cells. However, the potential of ADCs extends well beyond cancer care. From autoimmune diseases to metabolic disorders, advancements in ADC technology are paving the way for breakthroughs across a range of therapeutic areas. This article explores how ADCs are redefining treatment paradigms and improving patient outcomes in diverse fields of medicine.

Read more
Sino_teaserSino Biological
Sino Biological

Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV

High-Quality HIV Antigens for Cutting-Edge Solutions

Read more
960-540
Sino Biological

Kinase inhibitors: Promising therapeutics for neurodegenerative diseases

Neurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) suffer from a scarcity of effective treatments. Current therapies primarily provide symptomatic relief but do not address the underlying pathology, failing to slow or halt disease progression. This underscores the urgent need to identify new therapeutic targets relevant to the pathology of these conditions. Kinases represent highly tractable drug targets, with kinase inhibitors achieving significant success, particularly in oncology. However, their potential in neurodegenerative diseases remains largely unexplored, presenting a promising avenue for future research and therapeutic development.

Read more
Sino BiologicalSino Biological
Sino Biological

Sino Biological and BioGeometry Deepen Strategic Cooperation to Empower Protein R&D with Generative AI

Sino Biological, a leading recombinant protein production company, is pleased to announce an expansion of its strategic partnership with BioGeometry, a pioneer in digital biology. This collaboration brings together Sino Biological’s advanced protein expression and wet-lab capabilities with BioGeometry’s generative AI protein design and optimization platform. The two companies aim to enhance their joint offerings and explore high-value market opportunities globally.

Read more
1860-1040
Sino Biological

Anti-payload Antibodies: Facilitating ADC PK studies

Antibody-drug conjugates (ADCs) are a new class of biotherapeutics, consisting of acytotoxic payload covalently bound to an antibody by a linker. Evaluating the pharmacokinetics (PK) properties of ADCs in preclinical and clinical studies is essential for their strategic design and successful development.

Read more
SINO_KW41.jpg
Sino Biological

Sino Biological Announces the Opening of its New US-Based Center for Bioprocessing

Sino Biological, Inc., is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA, adjacent to the world-renowned Texas Medical Center.

Read more
Figure 1. The flow chart of CAR-NK therapy.
Sino Biological

CAR-NK Therapy: An Effective Strategy for Cancer Treatment

CAR-T therapies represent a new successful strategy for the treatment of hematological malignancies; however, recent studies have revealed some limitations, including the occurrence of graft-versus-host disease (GVHD), neurotoxicity, and cytokine release syndromes (CRS). This has prompted researchers to look for alternative, safer cells, such as natural killer (NK) cells 1. NK cells are lymphocytes that kill tumor cells and virus-infected cells non-specifically, without prior sensitization. CAR-NK therapy involves the modification of NK cells with mature chimeric antigen receptor (CAR) technology to exploit their unique target cell recognition mechanism and broad tumor-killing ability. Figure 1 illustrates the CAR-NK therapeutic strategy 1. Compared with CAR-T therapy, CAR-NK therapy has numerous advantages, such as lower GVHD and significantly reduced CRS toxicity and immune effector cell-associated neurotoxicity syndrome toxicity, which enhance overall safety 2, 3. In addition, NK cells have multiple tumor recognition sites, thus potentially reducing antigenic escape failure 4.

Read more